Summer Sale
50% off Premium Yearly
Opinions Jon Vialoux
Gilead Sciences Inc.GILDPAST TOP PICKAug 14, 2015
Stock price when the opinion was issued
As of Jun 16, 2026. Market Open.
You might be interested:
It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Has long owned this, because it's a value stock and keeps raising its dividend.
Brian Belski
Jim Lebenthal;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
(A Top Pick June 11/15. Down 2.6%.) Biotech has a period of seasonal strength from June 22 to September 12. Average gains during that time are about 12%. This one is a bit different in that it starts it seasonal strength at about May and runs through to September 12. It had a giant consolidation from about October to April and then broke above resistance, followed by an up leg, followed by another consolidation. There is nothing negative about the stock yet. You should expect to see higher returns ahead. On biotechs, there is a bit of a negative sentiment turning to them because investors are trying to gain a top in the market. Chart shows a bit of a head and shoulders pattern, and we are below the support right now.